Regeneron Pharmaceuticals, Inc.Profile
|
|
Share Price & Volume
| Previous Close | $764.93 | |
| Open | -0.79% | $758.90 |
| Day Low | -2.24% | $747.82 |
| Day High | -0.29% | $762.70 |
| 52-Week Low | -37.71% | $476.49 |
| 52-Week High | +7.34% | $821.11 |
| Day Volume | 483,643 | |
| Average Volume | 820,728 | |
| EPS (TTM) | $41.49 | |
| P/E (TTM) | 18.31x | |
| FWD P/E (NTM) | 17.70x | |
| Next Earnings Date | Apr 29, 2026 |
| Market Cap | 78,951,475,228 | |
| Shares Outstanding (Millions) | 103,902,660 | |
| Dividend | $3.52 (0.46%) | |
| Beta | 0.40 | |
| ROE | 0.15% | |
| ROA | 0.06% |
Analyst Ratings and Price Targets
Current:
$759.86
Average:
$838.07
(+10.29%)
Low:
$745.00
(-1.96%)
High:
$975.00
(+28.31%)
| Barclays | Initiates Coverage On | Overweight | $923.00 | +21.47% | Mar 5, 2026 |
| RBC Capital | Maintains | Sector Perform | $765.00 | +0.68% | Mar 1, 2026 |
| Guggenheim | Maintains | Buy | $975.00 | +28.31% | Feb 9, 2026 |
| JP Morgan | Maintains | Overweight | $950.00 | +25.02% | Feb 2, 2026 |
| Oppenheimer | Reiterates | Outperform | $865.00 | +13.84% | Feb 2, 2026 |
| Morgan Stanley | Maintains | Equal-Weight | $769.00 | +1.20% | Feb 2, 2026 |
| Wells Fargo | Maintains | Equal-Weight | $800.00 | +5.28% | Feb 2, 2026 |
| Cantor Fitzgerald | Maintains | Overweight | $800.00 | +5.28% | Feb 2, 2026 |
| Truist Securities | Maintains | Buy | $818.00 | +7.65% | Feb 2, 2026 |
| Evercore ISI Group | Maintains | Outperform | $875.00 | +15.15% | Jan 22, 2026 |
| Truist Securities | Maintains | Buy | $820.00 | +7.91% | Jan 8, 2026 |
| B of A Securities | Upgrades | Buy | $860.00 | +13.18% | Jan 7, 2026 |
| Morgan Stanley | Maintains | Equal-Weight | $768.00 | +1.07% | Dec 12, 2025 |
| Wells Fargo | Maintains | Equal-Weight | $745.00 | -1.96% | Dec 10, 2025 |
Headquarters
Tarrytown, NY, USA
Sector
Industry
# of Employees
15,158